Taking the Road Less Traveled: Following Molecular Trail Markers.
Clin Cancer Res
; 28(20): 4357-4359, 2022 10 14.
Article
em En
| MEDLINE
| ID: mdl-35960159
ABSTRACT
Targeted therapy largely remains an unmet therapeutic need for low-grade serous ovarian carcinomas. However, recent advances in molecular characterization are beginning to change the landscape. A recent article highlights the association of genetic alterations with clinical outcomes, widening the scope of novel targeted therapies. See related article by Manning-Geist et al., p. 4456.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Ovarianas
/
Neoplasias Peritoneais
/
Cistadenocarcinoma Seroso
Tipo de estudo:
Diagnostic_studies
Limite:
Female
/
Humans
Idioma:
En
Revista:
Clin Cancer Res
Ano de publicação:
2022
Tipo de documento:
Article